The global antisense therapy market is influenced by the development of exon-skipping therapies for selected genetic disorders. These medicines can alter RNA splicing to help cells produce a modified protein, creating a therapeutic option for certain mutations that affect protein production. The antisense therapy market was valued at US$ 6.17 billion in 2025 and is projected to reach US$ 24.5...